阈下微脉冲激光(577 nm)治疗慢性中央性浆液性脉络膜视网膜病变患者的功率调节方法(试点研究)。

IF 1.8 4区 医学 Q3 OPHTHALMOLOGY
Journal of Ophthalmology Pub Date : 2024-10-08 eCollection Date: 2024-01-01 DOI:10.1155/2024/9750395
Taras Kustryn, Oleg Zadorozhnyy, Illia Nasinnyk, Nataliya Pasyechnikova, Andrii Korol
{"title":"阈下微脉冲激光(577 nm)治疗慢性中央性浆液性脉络膜视网膜病变患者的功率调节方法(试点研究)。","authors":"Taras Kustryn, Oleg Zadorozhnyy, Illia Nasinnyk, Nataliya Pasyechnikova, Andrii Korol","doi":"10.1155/2024/9750395","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To study the safety and effectiveness of subthreshold micropulse (SML) 577 nm laser therapy with an individual power titration in treating patients with chronic central serous chorioretinopathy (CSC).</p><p><strong>Methods: </strong>The study was a prospective, single-centre observation of 30 patients (30 eyes) with chronic CSC. All patients with chronic CSC were treated with a 577 nm micropulse laser. Individual power parameters for each patient were titrated in a micropulse mode. The primary outcome measure was best-corrected visual acuity (BCVA) at 6-month follow-up. The secondary outcome measures were as follows: central retinal thickness (CRT) and maximum subretinal fluid height (SRFH) according to optical coherence tomography, number of laser sessions, and treatment safety at 6-month follow-up.</p><p><strong>Results: </strong>Before treatment, the mean BCVA was 0.35 ± 0.16, the mean CRT was 285 ± 76 µm, and the mean SRFH was 311 ± 85 µm. Six months after 577 nm SML therapy, there was a statistically significant increase in the mean BCVA with the maximum correction to 0.45 ± 0.15 (<i>p</i> = 0.001). The mean CRT and SRFH decreased significantly to 236 ± 45 <i>μ</i>m (<i>p</i> = 0.003) and 45 ± 25 <i>μ</i>m (<i>p</i> = 0.001), respectively. At the end of the follow-up, complete resorption of the subretinal fluid was noted in 50% (15 eyes), and in 43% (13 eyes), a decrease in the SRFH was observed. During the entire observation period, 25 patients underwent 1 session of 577 nm SML therapy, 2 patients underwent 2 sessions, and 3 patients underwent the intervention three times.</p><p><strong>Conclusion: </strong>SML 577 nm therapy with individual selection of laser power in a micropulse mode is a safe and effective method of treating patients with chronic CSC. Further studies are needed to test the long-term safety and efficacy of 577 nm SML therapy with individual power settings in chronic CSC.</p>","PeriodicalId":16674,"journal":{"name":"Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479767/pdf/","citationCount":"0","resultStr":"{\"title\":\"Subthreshold Micropulse Laser (577 nm) Therapy with an Individual Approach for Power Titration in Patients with Chronic Central Serous Chorioretinopathy (Pilot Study).\",\"authors\":\"Taras Kustryn, Oleg Zadorozhnyy, Illia Nasinnyk, Nataliya Pasyechnikova, Andrii Korol\",\"doi\":\"10.1155/2024/9750395\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To study the safety and effectiveness of subthreshold micropulse (SML) 577 nm laser therapy with an individual power titration in treating patients with chronic central serous chorioretinopathy (CSC).</p><p><strong>Methods: </strong>The study was a prospective, single-centre observation of 30 patients (30 eyes) with chronic CSC. All patients with chronic CSC were treated with a 577 nm micropulse laser. Individual power parameters for each patient were titrated in a micropulse mode. The primary outcome measure was best-corrected visual acuity (BCVA) at 6-month follow-up. The secondary outcome measures were as follows: central retinal thickness (CRT) and maximum subretinal fluid height (SRFH) according to optical coherence tomography, number of laser sessions, and treatment safety at 6-month follow-up.</p><p><strong>Results: </strong>Before treatment, the mean BCVA was 0.35 ± 0.16, the mean CRT was 285 ± 76 µm, and the mean SRFH was 311 ± 85 µm. Six months after 577 nm SML therapy, there was a statistically significant increase in the mean BCVA with the maximum correction to 0.45 ± 0.15 (<i>p</i> = 0.001). The mean CRT and SRFH decreased significantly to 236 ± 45 <i>μ</i>m (<i>p</i> = 0.003) and 45 ± 25 <i>μ</i>m (<i>p</i> = 0.001), respectively. At the end of the follow-up, complete resorption of the subretinal fluid was noted in 50% (15 eyes), and in 43% (13 eyes), a decrease in the SRFH was observed. During the entire observation period, 25 patients underwent 1 session of 577 nm SML therapy, 2 patients underwent 2 sessions, and 3 patients underwent the intervention three times.</p><p><strong>Conclusion: </strong>SML 577 nm therapy with individual selection of laser power in a micropulse mode is a safe and effective method of treating patients with chronic CSC. Further studies are needed to test the long-term safety and efficacy of 577 nm SML therapy with individual power settings in chronic CSC.</p>\",\"PeriodicalId\":16674,\"journal\":{\"name\":\"Journal of Ophthalmology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479767/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Ophthalmology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/2024/9750395\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2024/9750395","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:研究阈下微脉冲(SML)577 nm 激光疗法在治疗慢性中心性浆液性脉络膜视网膜病变(CSC)患者中的安全性和有效性:该研究是一项前瞻性单中心观察项目,共观察了 30 名慢性 CSC 患者(30 只眼)。所有慢性 CSC 患者都接受了 577 nm 微脉冲激光治疗。在微脉冲模式下对每位患者的功率参数进行了调整。主要结果指标是随访6个月时的最佳矫正视力(BCVA)。次要结果指标如下:光学相干断层扫描显示的视网膜中央厚度(CRT)和最大视网膜下积液高度(SRFH)、激光治疗次数以及随访 6 个月时的治疗安全性:治疗前,BCVA 平均值为 0.35 ± 0.16,CRT 平均值为 285 ± 76 µm,SRFH 平均值为 311 ± 85 µm。577 nm SML 治疗 6 个月后,BCVA 平均值显著增加,最大校正值为 0.45 ± 0.15(p = 0.001)。平均 CRT 和 SRFH 显著下降,分别为 236 ± 45 μm (p = 0.003) 和 45 ± 25 μm (p = 0.001)。随访结束时,50% 的患者(15 眼)发现视网膜下积液完全吸收,43% 的患者(13 眼)观察到 SRFH 下降。在整个观察期间,25 名患者接受了 1 次 577 nm SML 治疗,2 名患者接受了 2 次治疗,3 名患者接受了 3 次干预:结论:在微脉冲模式下单独选择激光功率的 577 nm SML 疗法是治疗慢性 CSC 患者的一种安全有效的方法。还需要进一步的研究来检验 577 nm SML 治疗慢性 CSC 的长期安全性和有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Subthreshold Micropulse Laser (577 nm) Therapy with an Individual Approach for Power Titration in Patients with Chronic Central Serous Chorioretinopathy (Pilot Study).

Purpose: To study the safety and effectiveness of subthreshold micropulse (SML) 577 nm laser therapy with an individual power titration in treating patients with chronic central serous chorioretinopathy (CSC).

Methods: The study was a prospective, single-centre observation of 30 patients (30 eyes) with chronic CSC. All patients with chronic CSC were treated with a 577 nm micropulse laser. Individual power parameters for each patient were titrated in a micropulse mode. The primary outcome measure was best-corrected visual acuity (BCVA) at 6-month follow-up. The secondary outcome measures were as follows: central retinal thickness (CRT) and maximum subretinal fluid height (SRFH) according to optical coherence tomography, number of laser sessions, and treatment safety at 6-month follow-up.

Results: Before treatment, the mean BCVA was 0.35 ± 0.16, the mean CRT was 285 ± 76 µm, and the mean SRFH was 311 ± 85 µm. Six months after 577 nm SML therapy, there was a statistically significant increase in the mean BCVA with the maximum correction to 0.45 ± 0.15 (p = 0.001). The mean CRT and SRFH decreased significantly to 236 ± 45 μm (p = 0.003) and 45 ± 25 μm (p = 0.001), respectively. At the end of the follow-up, complete resorption of the subretinal fluid was noted in 50% (15 eyes), and in 43% (13 eyes), a decrease in the SRFH was observed. During the entire observation period, 25 patients underwent 1 session of 577 nm SML therapy, 2 patients underwent 2 sessions, and 3 patients underwent the intervention three times.

Conclusion: SML 577 nm therapy with individual selection of laser power in a micropulse mode is a safe and effective method of treating patients with chronic CSC. Further studies are needed to test the long-term safety and efficacy of 577 nm SML therapy with individual power settings in chronic CSC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Ophthalmology
Journal of Ophthalmology MEDICINE, RESEARCH & EXPERIMENTAL-OPHTHALMOLOGY
CiteScore
4.30
自引率
5.30%
发文量
194
审稿时长
6-12 weeks
期刊介绍: Journal of Ophthalmology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to the anatomy, physiology and diseases of the eye. Submissions should focus on new diagnostic and surgical techniques, instrument and therapy updates, as well as clinical trials and research findings.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信